Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases

• Published in: Annual review of medicine 2016-01, Vol.67 (1), p.337-353
• Main Authors: Fragoulis, George E, Siebert, Stefan, McInnes, Iain B
• Format: Article
• Language: English
• Subjects: Animals; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Arthritis, Psoriatic - drug therapy; Arthritis, Rheumatoid - drug therapy; Clinical Trials as Topic; Crohn Disease - drug therapy; Cytokines; Drug therapy; Humans; IL-23 IL-17 axis; Immunologic Factors - adverse effects; Immunologic Factors - therapeutic use; interleukin-17; Interleukin-17 - antagonists & inhibitors; Interleukin-17 - metabolism; interleukin-23; Interleukin-23 - antagonists & inhibitors; Interleukin-23 - metabolism; Pathogenesis; psoriasis; Psoriasis - drug therapy; Psoriasis - immunology; psoriatic arthritis; Spondylitis, Ankylosing - drug therapy; T cell receptors; Ustekinumab - therapeutic use
• ISSN: 0066-4219; 1545-326X
• DOI: 10.1146/annurev-med-051914-021944

The discovery of the biological functions of the interleukin-23 -17 axis led to the identification of IL-23 and IL-17 as important participants in the pathogenesis of several immune-mediated diseases. Therapeutic agents targeting these cytokines and or their receptors have now been developed as potential treatment strategies for common immune-mediated diseases. Anti-IL-17 and anti-IL-12 -23 regimens appear particularly effective in psoriasis, with promising results in spondyloarthropathies also emerging. Overall, these agents appear well tolerated, with adverse-event rates that are commensurate with those in other biologic treatment programs. The strategic utility of these new agents, however, remains uncertain, and further studies will be required to determine their place in the context of existing conventional and biologic immune-modifying agents.